当前位置:
X-MOL 学术
›
Emerg. Infect. Dis.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effectiveness of BNT162b2 Vaccine in Adolescents during Outbreak of SARS-CoV-2 Delta Variant Infection, Israel, 2021
Emerging Infectious Diseases ( IF 11.8 ) Pub Date : 2021-09-27 , DOI: 10.3201/eid2711.211886 Aharona Glatman-Freedman , Yael Hershkovitz , Zalman Kaufman , Rita Dichtiar , Lital Keinan-Boker , Michal Bromberg
中文翻译:
BNT162b2 疫苗在 SARS-CoV-2 Delta 变异感染爆发期间对青少年的有效性,以色列,2021
更新日期:2021-09-28
Emerging Infectious Diseases ( IF 11.8 ) Pub Date : 2021-09-27 , DOI: 10.3201/eid2711.211886 Aharona Glatman-Freedman , Yael Hershkovitz , Zalman Kaufman , Rita Dichtiar , Lital Keinan-Boker , Michal Bromberg
In Israel, the BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 was approved for use in adolescents in June 2021, shortly before an outbreak of B.1.617.2 (Delta) variant–dominant infection. We evaluated short-term vaccine effectiveness and found the vaccine to be highly effective among this population in this setting.
中文翻译:
BNT162b2 疫苗在 SARS-CoV-2 Delta 变异感染爆发期间对青少年的有效性,以色列,2021
在以色列,针对严重急性呼吸系统综合症冠状病毒 2 的 BNT162b2 疫苗于 2021 年 6 月被批准用于青少年,就在 B.1.617.2 (Delta) 变异显性感染爆发前不久。我们评估了短期疫苗的有效性,发现疫苗在这种情况下对这一人群非常有效。